Memantine Hydrochloride Tablet, Film Coated
Product Images NDC 71335-1908

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 71335-1908). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351908)

This is a packaging label for medication called Namenda 10mg Tablet manufactured by Sun Pharma Industries Ltd. The pack contains 30 tablets and should be stored at a temperature range of 20°C to 25°C. The label also includes a unique identification number (NDC) for the medication. Keep it out of reach of children.*

FDA Label Image

Spl-memantine-chemical-structure (Spl Memantine Chemical Structure)

FDA Label Image

Spl-memantine-figure1 (Spl Memantine Figure1)

The text describes a figure that shows the time course of Clinical Improvement or Clinical Decline scored by patients in a treatment that include Placebo and Memantine Hydrochloride. The x-axis measures the Weeks of Treatment, while the y-axis measures the change from baseline in ADCS-ADL score.*

FDA Label Image

Spl-memantine-figure2 (Spl Memantine Figure2)

The text describes a graph or chart showing the cumulative percentage of patients completing 28 weeks of double-blind treatment using placebo and Memantine Hydrochloride drugs. The graph displays the changes from Baseline in ADCS-ADL scores. No further information is available.*

FDA Label Image

Spl-memantine-figure3 (Spl Memantine Figure3)

The text describes a figure labeled as "Figure 3", which shows the time course of changes in SIB (Severe Impairment Battery) score for patients who completed 28 weeks of treatment. The figure includes two lines, one for placebo and the other for a drug called memantine hydrochloride, and shows the mean change from baseline for each treatment group at weeks 8, 12, 16, and 20. The figure also includes two labeled sections for "Clinical Improvement" and "Clinical Decline". No further information is available in the text.*

FDA Label Image

Spl-memantine-figure4 (Spl Memantine Figure4)

The text is a graph titled "Cumulative percentage of patients completing 28 weeks of double-blind treatment with specified changes from baseline in SIB scores" with two lines labelled "Placebo" and "Memantine Hydrochloride". The x-axis measures the change from baseline in SIB scores in intervals of -30, -25, -20, -15, -10, -5, 0, 5, 10, 15, 20, and 25. The y-axis measures the cumulative percentage of patients in intervals of 0, 10, 20, 30, and 40. No further information is available to generate a useful description.*

FDA Label Image

Spl-memantine-figure5 (Spl Memantine Figure5)

The text describes a figure that shows the clinical improvement in ADCS-ADL score for patients completing 24 weeks of treatment with either a placebo/donepezil or memantine hydrochloride/donepezil. The graph shows the time course of change from baseline scores on the y-axis and the weeks of treatment on the x-axis. The figure suggests that memantine hydrochloride in combination with donepezil may improve the ADCS-ADL score compared to placebo. There is also a mention of "Mean (+SEM) Change from Baseline" in relation to clinical decline, but there is no further information on this.*

FDA Label Image

Spl-memantine-figure6 (Spl Memantine Figure6)

FDA Label Image

Spl-memantine-figure7 (Spl Memantine Figure7)

FDA Label Image

Spl-memantine-figure8 (Spl Memantine Figure8)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.